دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
- :
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Politics and pharma: hurdles in UK science ambitions
doi : 10.1016/S1470-2045(25)00375-4
Volume 26, Issue 7, July 2025, Page 817
Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope?
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate cancer
Demystifying the WHO Model Lists of Essential Medicines for cancer care
Hormonal therapy for young-onset breast cancer: current understanding and lessons
Improved recruitment equity in a UK cancer genomic testing programme
Cancer care in Bahrain: progress, challenges, and strategic priorities
From conflict to care: rebuilding Syria's oncology infrastructure
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
SANO trial: innovations, risks, and unanswered questions – Authors' reply
Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply
Practice standard in British Colombia impacting opioid prescriptions for people with cancer
First-in-world “Trojan horse� drug offered to multiple myeloma patients in England
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort
Transforming cancer care in Jordan: a 10-year comprehensive patient-centred strategy guided by local experts
Qatar national cancer care and research: pioneering strategies for global health excellence
Bridging borders for resilience in cancer control in the Middle East: a strategic alliance of Saudi Arabia, Qatar, and Jordan
